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Role of adhesion molecules in the induction of
restenosis after angioplasty in the lower limb
Peter Heider, MD,a Moritz Georg Wildgruber, MD,a Wolfgang Weiss, MD,b Hermann Jakob Berger, MD,b
Eckstein Hans Henning, MD,a andOliver Wolf, MD,a Munich, Germany
Objective: The adhesion molecules P selectin, E selectin, intercellular adhesion molecule, vascular cellular adhesion
molecule (VCAM), and monocyte chemoattractant protein 1 play a important role in the development of arteriosclerotic
lesions and are considered main contributors to restenosis after angioplasty. We expected that the serum levels of these
markers would increase in the early phase of the first few weeks after angioplasty.
Methods:We assessed prospectively the levels of soluble forms of adhesion molecules on the day before and then 24 hours
and 2 and 4 weeks after angioplasty in arteries of the lower limb by using enzyme-linked immunosorbent assays. We
investigated the distribution pattern of these markers in 44 patients (25 male and 19 female; age, 67.7  8.5 years [mean 
SD]) presenting with intermittent claudication (Fontaine stage IIb). Twelve patients (27.3%) underwent diagnostic
angiography, 32 (72.2%) received interventional treatment, 22 (68.8%) received balloon angioplasty, and 10 (31.2%)
required stent placement.
Results: Ten (31.3%) of the treated patients developed restenosis within 6 months. These patients had significantly higher
levels of P selectin (P  .034), E selectin (P  .006), and VCAM (P  .050) at all time points. E selectin, VCAM, and
monocyte chemoattractant protein 1 levels increased between 24 hours and 4 weeks after angiographic procedures, thus
indicating that the angiographic procedure itself leads to activation and inflammation of the endothelium.
Conclusions: This study emphasizes a meaningful role of the adhesion molecules E selectin, P selectin, and VCAM
as interesting contributors to restenosis formation after percutaneous transluminal angioplasty. ( J Vasc Surg 2006;43:
969-77.)Until now, restenosis has remained a major limitation
to the clinical usefulness of percutaneous transluminal an-
gioplasty (PTA). Despite a primary success rate as high as
90%,1 the incidence of chronic restenosis resulting mostly
from vascular smooth muscle cell proliferation after PTA
has been reported to be as high as 40% within 6 months.2,3
Also, a trend toward primary stenting did not improve the
patency rate significantly.4,5 The process of restenosis has
been extensively studied after coronary angioplasty,6 but
the process of peripheral intimal thickening and the thera-
peutic conclusions are still poorly investigated. Changes in
the endothelial function, migration of leucocytes across the
endothelium, myointimal proliferation, platelet aggrega-
tion, and thrombus formation seem to be major reasons for
recurrent lesions after PTA. Atherosclerosis and restenotic
lesions are characterized by the infiltration of leucocytes
into foci of inflammation.7,8 Ross9 showed that the cells
recruited are primarily monocytes. In the initiation of
monocyte migration into the vascular wall, adhesion mol-
ecules play a significant role. The molecules of the selectin
family—P (platelet) selectin and E (endothelial) selectin—
mediate the adhesion of monocytes on the activated endo-
thelium.10-12 The interaction between the selectins and
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doi:10.1016/j.jvs.2005.11.061the monocytes allows chemokines such as monocyte
chemoattractant protein (MCP)-1, which is presented
on the surface of endothelial cells, to activate mono-
cytes.13 The monocytes can subsequently bind to endo-
thelial cell adhesion molecules such as intercellular adhe-
sion molecule (ICAM)-1 and vascular cellular adhesion
molecule (VCAM)-1.12-16
A variant of these adhesion molecules, released from
the cell surface of endothelial cells and platelets, can be
detected as circulating soluble molecules in the blood. We
investigated the performance of the soluble forms of the
adhesion molecule P selectin, E selectin, VCAM, ICAM,
andMCP-1 in patients in the early course after angiography
and interventional therapy in the lower limb to focus on
their role in the endothelial answer to angioplasty-induced
injury and to get a better understanding of the delayed
failure of angioplasty due to restenosis development.
PATIENTS AND METHODS
Patients. Forty-four patients (25 men and 19 women;
mean age, 67.7  8.5 years) with peripheral arterial occlu-
sive disease and indications for an interventional procedure
were enrolled between July 2003 and December 2004. All
patients presented with symptoms of intermittent claudica-
tion (Fontaine stage IIb). The severity of the peripheral
arterial occlusive disease was assessed by measurement of
the ankle/brachial index at rest and by the treadmill test,
and morphologic graduation of the lesions was performed
noninvasively by duplex sonography (System Five; Ving-
med Sounds A/S, Horten, Norway). The patients had a
walking interval free of pain of 110.0  60.7 m. Patient
characteristics are listed in Table I.
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the World Medical Association Declaration of Helsinki. All
patients gave written and informed consent, and the study
was approved by the Review Board Committee of the
Interdisciplinary Center for Vascular Diseases of the Tech-
nical University of Munich. Patients with documented
malignant diseases, vasculitis, or both were excluded. All
medications for concomitant diseases except coumarin de-
rivatives were continued during study participation. Medi-
cation status is shown in Table I.
Lesions. Twenty patients (45.5%) had lesions in the
iliac artery, 20 patients (45.5%) had lesions in the superficial
femoral artery, and 4 patients (9.1%) had lesions in the
popliteal artery. Thirty-three patients (75%) had stenosis,
and 11 patients (25%) had occlusion of the vessel. In
patients with stenotic lesions, the average lumen narrowing
was 82.3%  13.6%, graded on an angiographic profile by
the performing radiologist. The descriptions of the lesions
are shown in Table II.
Angiography and angioplasty procedures. All pa-
tients received diagnostic digital subtraction angiography
Table I.
Patient Characteristics
Angiography
(n  12)
Age (in years)* 68,75  9,34
BMI (in kg/m2)* 28,09  6,14
Sex†
Male 8 (66,7)
Female 4 (33,3)
Risk factors†
Hypertension 9 (75)
Hypercholesterolemia 9 (75)
Obesity 3 (25)
Diabetes
IDDM 0 (0)
NIDDM 4 (33,3)
Dialysis 0 (0)
Tobacco use 8 (66,7)
Other arteriosclerotic diseases†
CAD 5 (41,7)
Carotid disease 3 (25)
Plasma levels
CRP 0,71  0,36
Fibrinogen 364,7  109,3
Pain-free walking distance* (m) 129,17  62
Ankle brachial index
Before intervention 0,66  0,34
At discharge 0,65  0,34
Medication†
Thrombocyte inhibitors 10 (83,3)
Vasodilators 4 (33,3)
Lipid-lowering agents 4 (33,3)
-blockers 5 (41,7)
ACE inhibitors 5 (41,7)
Note
*Data are mean  SD.
†Data are numers of patients unless otherwise indicated; numbers in parent
‡P value obtained with Kruskal-Wallis test.
P value obtained with Fisher’s exact test.
§P value obtained with Chi Square test.
#P value obtained with the Mann-Whitney U test.of the lower limbs before interventional treatment. A non-ionic contrast material, iomeprol (Imeron 300; Altana
Pharma GmbH, Konstanz, Germany), was used: 178.3 
66.0 mL per patient. Of 44 enrolled patients, 32 (72.7%)
received interventional treatment, and 12 (27.3%) received
only diagnostic angiography. Of the 32 treated patients, 22
patients (68.8%) received balloon angioplasty, and 10 pa-
tients (31.2%) required secondary stent implantation be-
cause of residual stenosis higher than 30% or flow-limiting
elastic recoil, dissection, or intimal flap. As stenting devices,
self-expanding nitinol stents (Xpert; Abbott Vascular De-
vices, Abbott Park, Ill) with diameters from 5 to 8 mm and
lengths from 20 to 60 mm were used. For the 12 patients
with sole angiography, 4 patients (33.3%) had stenotic
lumen narrowing less than 50%, and 8 patients (66.6%) had
occluded segments longer than 10 cm. After the procedure,
22 patients (50%) had a 3-vessel runoff, 19 patients (43.2%)
had a 2-vessel runoff, and only 3 patients (6.8%) had a
1-vessel-runoff.
Angiography and angioplasty procedures were per-
formed according to established and accepted tech-
niques.17,18 The interventions were performed by two ex-
Balloon
(n  22)
Stenting
(n  10)
Total
(n  44)
69,5  8,58 62,3  4,6 67,66  8,45
4,54  4,01 25,47  2,21 25,72  4,57
12 (54,5) 5 (50) 25 (56,8)
10 (45,5) 5 (50) 19 (43,2)
18 (81,8) 9 (90) 36 (81,8)
13 (59,1) 7 (70) 29 (65,9)
2 (9.1) 0 (0) 5 (11,4)
2 (9,1) 0 (0) 2 (4,5)
3 (13,6) 1 (10) 8 (18,2)
1 (4,5) 1 (10) 2 (4,5)
18 (81,8) 9 (90) 35 (79,5)
3 (13,6) 3 (30) 11 (25)
5 (22.7) 1 (10) 9 (20,5)
0,76  0,53 0,81  0,63 0,76  0,51
13,8  157,7 353,5  76,2 381,4  116,8
9,55  57,94 110  65,83 110  60,73
0,66  0,23 0,62  0,28 0,65  0,27
0,86  0,2 0,89  0,28 0,81  0,27
18 (81,8) 9 (90) 37 (84,1)
8 (36,4) 5 (50) 17 (38,6)
10 (45,5) 4 (40) 18 (40,9)
10 (45,5) 5 (50) 20 (45,5)
9 (40,9) 7 (70) 21 (47,7)
are percentages.2
4
9
hesesperienced interventional radiologists (W.W. and H.B.). All
(70)
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one patient (2.27%) required surgical revision as a result of
bleeding at the puncture site. A bolus of 3000 to 5000 IU
of unfractionated heparin was given intra-arterially as anti-
thrombotic prophylaxis. After PTA, acetylsalicylate acid
100 mg/d and clopidogrel 75 mg/d were given as stan-
dard treatment. Further characteristics of the performed
procedures are listed in Table II.
Laboratory tests. Venous blood samples for labora-
tory testing were drawn in pyrogen-free tubes on the day
before the interventional procedure (between 10:00 and
12:00 AM) and 24 hours after the intervention, as well as 2
and 4 weeks later. In patients who received only angio-
graphic procedures, the samples were obtained at the same
time points. Blood samples were immediately centrifuged
at 2500 rpm for 5 minutes, and the obtained serum was
stored at70° C until laboratory testing. According to the
results of Pai et al,19 who investigated the stability of novel
plasma markers in different time ranges from specimen
collection until processing, the time range from sample
collection until freezing was held to a maximum of 2 hours.
Stored samples were thawed and assayed for P selec-
tin, E selectin, VCAM, ICAM, and MCP-1 by using
commercially available enzyme-linked immunosorbent
assay (ELISA) kits (Biosource International, Camarillo,
Calif) according to the manufacturer’s specifications. Stan-
Table I. Continued.
P value
No restenosis
(n  22)
Re
(n
0,035‡ 68,32  9,23 64,9
0,230‡ 24,1  3,29 26,43
0,785‡§
12 (54,5) 5
10 (45,5) 5
0,779 18 (81,8) 9
0,706 11 (50) 9
0,209 1 (4,5) 1
0,498
0 (0) 2
2 (9,1) 2
0,477 1 (4,5) 1
0,387 20 (90,9) 7
0,159 4 (18,2) 2
0,788 3 (13,6) 3
0,996 0,86  0,63 0,6
0,670 351,7  124,2 457,7
0,423 113,18  62,37 80
0,949 0,7  0,178 0,54
0,083 0,91  0,14 0,78
0,999 18 (81,8) 9
0,778 6 (27,3) 7
0,920 7 (31,8) 7
0,926§ 8 (36,4) 7
0,306§ 9 (40,9) 7dardization was performed by using the recombinant adhe-sion molecules provided with the kits. An ELISA reader
(Dynatech Laboratories, Chantily, VA, USA) set to 450
nm with the wavelength correction set to 620 nm deter-
mined the optical density. The minimum detectable levels
were 1.3 ng/mL for P selectin, 0.5 ng/mL for E selectin,
0.9 ng/mL for VCAM, 0.5 ng/mL for ICAM, and 20
pg/mL for MCP-1. The vascular surgeons who performed
the follow-up ultrasound studies, as well as the performing
radiologists, were blinded to the laboratory results.
Follow-up. Clinical examination and ankle/brachial
index analyses were performed on the day before the
interventional procedure, on the day of discharge, and 2
and 4 weeks as well as 6 months after intervention. The
end point of the study was the development of restenosis
within 6 months, defined as a reduction of the lumen
diameter more than 50% at the site of PTA. Before the
intervention, all lesions were scanned and graded by
duplex sonography. Lumen diameters were measured on
angiographic profile immediately after angioplasty and
verified by duplex sonography. After 6 months, all PTA
sites were scanned by duplex sonography, and the lumen
diameters of the treated segments were measured and
compared with the result after PTA, according to the
Jäger/Strandness classification.20 This technique has
been widely accepted, and a sensitivity of 92% and spec-
ificity of 98% have been reported.21,22 Therefore, the
sis
)
Total
(n  32) P value
,96 87,25  8,22 0,142#
,71 24,83  3,54 0,077#
0,811§
17 (53,1)
15 (46,9)
27 (84,4) 0,555§
20 (62,5) 0,030§
2 (6,3) 0,555§
0,053§
2 (6,3)
4 (12,5)
2 (6,3) 0,555§
27 (84,4) 0,131§
6 (18,8) 0,903§
6 (18,8) 0,272§
,29 0,77  0,55 0,424#
12,5 387  124,9 0,243#
8,31 102.81  59,64 0,130#
,33 0,65  0,24 0,300#
,33 0,87  0,22 0,338#
27 (84,4) 0,555§
13 (40,6) 0,023§
14 (43,2) 0,044§
15 (46,9) 0,077§
16 (50) 0,127§steno
 10
 4
 3
(50)
(50)
(90)
(90)
(10)
(20)
(20)
(10)
(70)
(20)
(30)
 0
 1
 4
 0
 0
(90)
(70)
(70)
(70)restenosis was defined morphologically and hemody-
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two experienced vascular surgeons (P.H. and O.W.).
The ultrasound studies were read in a blinded manner.
Statistics. Results are given as mean  SD. Two-
group comparisons of patient characteristics were per-
formed with the 2 test or the Mann-Whitney U test.
Three-group comparisons of patient characteristics were
performed by using the Fisher exact test or Kruskal-
Wallis test. Comparisons between groups of the growth
factor levels and comparisons between the nonrestenotic
and restenotic groups were analyzed by repeated analysis
of variance. Analysis of medication and risk factors was
planned as univariate analysis in consideration of the
small observation group. A probability level of .05 or less
was considered to be statistically significant. All analyses
Table II.
Angiographic and procedural
characteristics
Angiography
(n  12)
Location of obstruction*
Iliac artery 3 (25)
TASC classification
TASC A 1 (33,3)
TASC B 0 (0)
TASC C 2 (66,7)
TASC D 0 (0)
Femoral artery 7 (58,3)
TASC classification
TASC A 1 (14,3)
TASC B 0 (0)
TASC C 3 (42,9)
TASC D 3 (42,9)
Popliteal artery 2 (16,7)
TASC classification
TASC A 0 (0)
TASC B 0 (0)
TASC C 1 (50)
TASC D 1 (50)
Mono-/bilateral stenosis*
Monolateral 3 (25)
Bilateral 9 (75)
Degree of obstruction†
Lumen obstruction (in %) 75,71  16,94
Length of stenosis (in cm) 5,14  2,79
Procedural characteristics
Used contrast material (in ml)† 168,3  57,5
Residual stenosis after
angioplasty (in %)† 1
Treatment of more than 1
stenosis in the same artery*
Complication requirering
surgical intervention*
Run of vessels after intervention*
3 run-off vessels 4 (33,3)
2 run-off vessels 7 (58,3)
1 run of vessel 1 (8,3)
Restenosis after 6 mo*
Note
*Data are numers of patients unless otherwise indicated, number in parenth
†Data are mean  SD.
‡P Value obtained with Fisher’s Exact Test.
§P Value obtained with Kruskal Wallis Test.were performed with SPSS 12.0 (SPSS Inc, Chicago, Ill).RESULTS
Patients and restenosis
Ten patients (31.25%) developed restenosis in the first
6 months after intervention. Table I shows the patient
characteristics of this group. Patients who developed reste-
nosis more often had hypercholesterolemia (P .030) and
had a higher trend toward diabetes (P .053) and a higher
body mass index (P  .077). They also showed a more
frequent use of vasodilators (P  .023) and statins (P 
.044) and a higher trend toward the use of -blockers (P
.077). The patient group comparisons showed no differ-
ences in sex, age, or other risk factors. Also, the baseline
levels of fibrinogen (P .243) and C-reactive protein (P
lloon
 22)
Stenting
(n  10)
Total
(n  44) P value
(45,5) 7 (70) 20 (45,5) 0,293‡
0,001‡
(90) 2 (28,6) 12 (60)
(10) 5 (71,4) 6 (30)
(0) 0 (0) 2 (10)
(0) 0 (0) 0 (0)
(45,5) 3 (30) 20 (45,5) 0,293‡
0,004‡
(80) 2 (66,7) 11 (55)
(20) 0 (0) 2 (10)
(0) 1 (33,3) 4 (20)
(0) 0 (0) 3 (15)
(9,1) 0 (0) 4 (9,1) 0,293‡
0,4‡
(33,3) 0 (0) 1 (20)
(67,7) 0 (0) 2 (40)
(0) 0 (0) 1 (20)
(0) 0 (0) 1 (20)
0,472‡
(45,5) 3 (30) 16 (36,4)
(54,5) 7 (70) 28 (63,6)
 13,77 90  4,63 82,29  13,58 0,233§
 0,97 2,63  1,9 2,63  2,07 0,022§
 64,1 164,5  80,6 178,3  66 0,354§
 11,43 2,0  4,22 10,63  11,34 0,003§
(9,1) 0 (0) 2 (4,5) 0,721‡
(4,5) 0 (0) 1 (2,3) 0,494‡
0,504‡
(59,1) 5 (50) 22 (50)
(31,8) 5 (50) 19 (43,2)
(9,1) 0 (0) 3 (6,8)
(22,7) 5 (50) 10 (31,3) 0,217‡
re percentages within group.Ba
(n
10
9
1
0
0
10
8
2
0
0
2
1
2
0
0
10
12
81,5
1,79
190
4,55
2
1
13
7
2
5
eses a.424) showed no effect on developing restenosis. Patients
molec
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 48.31 m) at the point of entry compared with the group
without restenosis (113.18 62.37 m; P .130). Patients
who required stent implantation were significantly younger
than others (P  .035). The comparison between resteno-
sis and the Transatlantic Inter-Society Consensus classifica-
tion of the primary target lesion showed no significant
difference (P  .540).
The measured levels of adhesion molecules are shown
in Table III. The courses of the serum levels are shown in
Table III. Time course of selectin, adhesion molecule, an
Variable
Angiography
(n  12)
Balloon
(n  22)
P selectin (ng/mL)
Before 45.7  8.5 50.1  8.3
24 h 40.7  11.0 39.3  7.8
2 wk 45.0  9.4 52.6  7.2
4 wk 38.7  8.7 54.0  8.8
P value .397 .397
E selectin (ng/mL)
Before 37.3  6.5 32.1  5.0
24 h 39.2  7.4 30.7  4.2
2 wk 38.1  7.2 33.6  4.9
4 wk 38.1  6.8 34.8  4.5
P value .733 .733
ICAM-1 (ng/mL)
Before 286.3  47.2 204.8  31.5
24 h 282.5  45.9 313.5  46.9
2 wk 261.0  45.0 325.0  60.7
4 wk 284.1  62.6 327.5  52.9
P value .286 .286
VCAM-1 (ng/mL)
Before 871.3  263.9 892.3  145.1
24 h 949.7  303.4 1156.3  204.2
2 wk 773.1  240.7 1039.4  138.3
4 wk 796.7  167.0 1030.4  159.2
P value .092 .092
MCP-1 (pg/mL)
Before 199.1  30.3 174.7  23.7
24 h 159.1  26.0 203.6  24.8
2 wk 222.9  35.6 187.1  26.8
4 wk 224.1  33.2 185.3  29.6
P value .890 .890
ICAM, Intercellular adhesion molecule; VCAM, vascular cellular adhesion
Data are given as mean  SD.
Fig 1. A,Mean levels of soluble E selectin. Levels rem
levels did not differ significantly among the three gro
restenosis (n  10) and patients who remained free
angioplasty. The E selectin levels in patients with reste
period (P  .006).Figs 1 to 5.Course of adhesion molecule levels after angiography
and angioplasty
Selectins. The levels of E selectin remained relatively
stable in the observed period; there was no significant
difference between time points (P  .981). Also, the type
of intervention (angiography, balloon angioplasty, or stent
implantation) showed no significant differences (P .733).
P selectin levels decreased significantly at 24 hours after
intervention in all three groups (P  .001), but the levels
P-1 levels
Stent
(n  10)
Without restenosis
(n  22)
Restenosis
(n  10)
74.8  15.0 55.3  9.0 63.5  14.2
44.1  14.6 27.6  4.8 69.8  16.7
61.7  12.4 45.8  5.9 76.7  13.3
65.5  11.4 49.3  8.0 75.8  12.4
.397 .034 .034
38.2  6.8 26.7  3.2 50.2  9.0
38.4  6.8 27.2  3.5 46.2  7.1
33.8  7.3 28.4  4.1 45.4  8.1
35.6  5.9 29.3  4.2 47.7  4.8
.733 .006 .006
352.2  58.3 228.6  41.5 299.9  30.5
435.1  57.2 327.8  45.7 403.6  67.1
373.3  84.2 279.4  52.4 473.6  96.1
354.8  45.9 293.3  46.8 430.1  62.1
.286 .057 .057
1325.5  340.0 972.4  196.7 1149.4  192.5
1190.0  135.7 1096.1  207.7 1322.5  84.7
1791.2  333.9 998.6  139.2 1880.8  306.5
1598.5  236.6 983.7  153.8 1701.1  224.0
.092 .050 .050
186.0  35.3 202.8  24.7 124.1  23.0
217.1  47.6 230.5  29.6 157.8  23.0
226.0  47.2 221.7  30.5 149.8  29.7
197.7  33.1 204.3  29.5 155.9  31.2
.890 .125 .125
ule; MCP, monocyte chemoattractant protein.
d stable over the observation period in all groups. The
P  .733). B, Mean levels in patients who developed
estenosis (n  22) after percutaneous transluminal
s were significantly higher over the entire observationd MCaine
ups (
of r
nosireturned close to their baseline values after 4 weeks. There
riod
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vention type (P  .397).
ICAM and VCAM. Whereas serum levels of ICAM
Fig 2. A, Mean levels of soluble P selectin. A decrease
was no significant difference between the intervention ty
levels of soluble P selectin. Over the entire period, P sele
than in those without (P  .034).
Fig 3. A,Mean levels of soluble intercellular adhesion m
was evident both in patients with balloon and in patients w
the entire observation period was not significant (P  .2
increased at 24 hours and stayed at the altered level, the d
not statistically significant over the entire observation pe
Fig 4. A, Mean levels of soluble VCAM-1. The V
compared with angiography and balloon angioplasty
(P .092). B,Mean levels of soluble VCAM-1. The leve
entire observation period (P  .050).
Fig 5. A,Mean levels of soluble monocyte chemoattrac
both in patients with balloon and with stent angioplast
course of time (P .890).B,Mean levels of solubleMCP
entire observation period (P  .125).remained stable over the entire observation period in pa-tients with single angiography, the levels both in patients
with balloons and in patients with stent angioplasty were
increased at 24 hours but remained negligibly increased at
electin levels was found in all groups at 24 hours. There
ver the entire observation period (P  .397). B, Mean
evels were significantly higher in patients with restenosis
ule (ICAM)-1. The increase of ICAM levels at 24 hours
ent angioplasty, although the course of serum levels over
,Mean levels of soluble ICAM. Although ICAM levels
nces between patients with and without restenosis were
(P  .057).
-1 levels after stent angioplasty were increased as
weeks, without significance in the course of time
atients with restenosis were significantly higher over the
protein (MCP)-1. The levels were increased at 24 hours
ompared with angiography, without significance in the
evels did not differ significantly between groups over thein P s
pes o
ctin lolec
ith st
86). B
iffereCAM
at 2
ls in ptant
y as c
-1. L2 and 4 weeks (P  .286). VCAM levels showed different
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observation period (P  .092). VCAM levels in patients
treated with stent angioplasty were significantly increased at
2 weeks after intervention (P  .024) and remained in-
creased at 4 weeks.
Monocyte chemoattractant protein 1. Although se-
rum levels of MCP-1 decreased in patients with singular
angiography at 24 hours, the levels increased in both pa-
tients with balloon and stent angioplasty (P  .890). After
4 weeks, almost all the patients had serum MCP-1 levels
close to their baseline values.
Course of adhesion molecule levels in patients with
and without restenosis
Selectins. The restenosis group had significantly
higher E selectin levels over the entire observation period
(P .006). P selectin levels showed a significant increase at
24 hours in patients who later developed restenosis com-
pared with those who did not (P  .034). The levels did
differ significantly considering restenosis development at
the other time points, although the values in the restenosis
group were higher at 4 weeks compared with their baseline
levels, whereas the group without restenosis did not exceed
their baseline levels at 4 weeks.
ICAM and VCAM. ICAM baseline values were
higher in the restenosis group, and levels remained higher
during the entire time course, but without reaching a
significant difference between the two groups (P  .057).
VCAM levels showed a significant increase in patients with
restenosis over the entire period (P  .050).
Monocyte chemoattractant protein 1. An inverse ef-
fectwas observed inMCP-1.The levels in the restenosis group
were lower than those in patients without restenosis over the
entire observation period, with a significant difference at 24
hours and 2weeks (P .021), whereas the difference over the
entire period was not significant (P .125).
DISCUSSION
Restenosis is the major limitation to the benefit of
angioplasty procedures. Adhesion molecules have been
identified to play a key role in the initiation process long
before restenotic lesions become clinically obvious and
angiographically visible. Because it is now widely accepted
that inflammation plays an important role in the formation
of arteriosclerotic lesions,9 it remains one of the major goals
to identify pathways that lead to leucocyte and platelet
recruitment into foci of inflammation. These pathways have
been extensively studied in coronary artery restenosis, but
knowledge about restenosis development after peripheral
PTA remains relatively poor. Tsakiris et al23 first investi-
gated the distribution pattern of adhesion molecules after
PTA in peripheral arterial occlusive disease, but their ob-
servations were restricted to the time points of 1 hour and
6 months after PTA. Because it has been proven multiple
times that initiation of restenosis takes place in the first few
weeks after PTA,6,24 our aim was to get an improved
overview of restenosis induction in the early time period
after angioplasty procedures. Therefore, we assessed thelevels of adhesion molecules before the procedure and 24
hours to 2 and 4 weeks after angioplasty. Because it is not
yet obvious to what degree contrast material used in inter-
ventions itself causes inflammation, we also measured the
marker levels in a group of patients who underwent only
diagnostic angiography.
Patients with later restenosis had significantly higher
baseline levels of E selectin, and the levels remained higher
over the entire observation period. This suggests a more
severe endothelial activation and damage that leads to a
higher inflammatory response of the vessel wall. P selectin
levels increased significantly in patients with restenosis
compared with those without it at 24 hours after angio-
plasty. This observation can be explained by the fact that E
selectin is a product only of endothelial cells,25 whereas P
selectin is stored in theWeibel-Palade bodies of endothelial
cells, as well as in the membrane of -granules of plate-
lets.26,27 One striking result is that E selectin levels were
even higher in patients with diagnostic angiography than in
patients with either kind of angioplasty procedure. To-
gether with the elevation of VCAM andMCP-1 levels at 24
hours (VCAM) and at 2 and 4 weeks (MCP-1) after an-
giography compared with their baseline levels before inter-
vention, this shows that the angiographic procedure itself
leads to a certain amount of endothelial activation and
inflammation. In accordance with previously published ob-
servations, this indicates that the radiographic contrast
material used for angiography interacts with the endothe-
lium and leads to a release of proinflammatory markers.
Other studies have found an increased platelet and endo-
thelial activation represented by increased levels of P selec-
tin and von Willebrand factor after angiography.28 Also, an
interaction between immunologic step processes in the
ELISA and the contrast material contributes to a shift of
cytokine levels.29
Both the levels of ICAM and VCAM were higher in
patients with restenosis than without, but without reaching
statistical significance in ICAM. The failure to achieve
statistical significance results from the high analytical vari-
ability that leads to a wide range of values and, thus, to a
high standard deviation. This is one of themajor limitations
of the ELISA method that has been already described.23
MCP-1 levels decreased uniformly at 15 minutes after
PTA and began to increase at 24 hours after the procedure.
This course is in accordance with the observation made in
the other adhesion molecules. The fact that MCP-1 shows
an inverse effect considering restenosis can be explained
with the specific function. After adhesion molecules trigger
binding of monocytes, MCP-1 regulates the recruitment
into the subendothelial space. Low levels of solubleMCP-1
correspond with a high endothelial affinity.
Opposed to the “just stent it” approach to the coronary
arteries, stenting in the peripheral vessels is performed
when balloon angioplasty itself is insufficient or when the
morphologic presentation of the lesion requires a stent. In
our study, secondary stenting was performed in case of
arterial dissection, intimal flap, or a residual stenosis after
balloon angioplasty higher than 30%. Patients being treated
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selectin, ICAM, and VCAM. Although the differences were
statistically not significant, the higher baseline levels in the
patients receiving stents indicate that these patients experi-
ence a greater burden of peripheral vascular disease, which
might predispose them to a higher restenosis rate. To make
sure that the higher serum levels obtained in the patients
with restenosis were not procedure dependent, we tested
for differences in the restenosis group between patients
being treated with balloons and patients treated with stent
angioplasty. Concerning restenosis, there was no significant
difference between patients being treated with balloons and
patients treated with stent angioplasty over the observed
period (P .05). Patients in the restenosis group showed a
higher risk profile for hypercholesterolemia and diabetes
and a higher body mass index, together with a more fre-
quent use of antiarteriosclerotic medication. This indicates
that these patients are at a higher risk for developing
restenosis and have to receive special clinical attention.10,30
In conclusion, our study shows that the circulating
adhesion molecules E selectin and P selectin, as well as
VCAM-1, are increased in patients with later restenosis
development. It also became evident that the angiographic
procedure itself leads to a certain increase in proinflamma-
tory pathways, especially in the selectins. This represents
ongoing endothelial damage induced by the radiographic
contrast material.
These results emphasize the important role of adhesion
molecules in restenosis development but also show that
marker levels in the period after angioplasty have to be inter-
preted extremely carefully.Modulation of the early inflamma-
tory response to angioplasty-induced vessel trauma, especially
through the interaction of adhesion molecules, remains a
promising opportunity for preventing restenosis formation
after peripheral angioplasty procedures.
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Over the last decade, attempts to identify and validate circu-
lating biomarkers predictive of cardiovascular disease have begun
to influence clinical practice, as well as to globally reshape thinking
on the pathophysiology of vascular events. Acute phase reactant
proteins, which classically reflect a response to acute injury or
infection, incorporate molecules with proinflammatory and proco-
agulant functions. Given the compelling evidence relating athero-
sclerosis to inflammation, the notion that circulating levels of such
molecules might be linked to the burden or activity of vascular
disease seems logical. For primary or secondary prevention pur-
poses, markers such as C-reactive protein offer utility in identifying
subgroups of patients at increased risk for long-term events, which
may be used to guide preventive nutritional, behavioral, and phar-
macologic therapies.1-3 Failure of vascular interventions, including
angioplasty, stenting, and surgical bypass, is a frequent problem
that clearly relates to the magnitude of the injury response. Iden-
tifying subgroups of patients at an elevated risk for aggressive
restenosis would be of great utility for the selection of optimal
interventions and quite possibly for guiding adjunctive medical or
other therapies to reduce the incidence of failure. To date, how-
ever, clinically useful biomarkers predictive of outcomes after
interventions have yet to be clearly identified. Data on the predic-
tive value of inflammatory markers in coronary interventions have
been conflicting, although one interesting study reported a bene-
ficial effect of targeted steroid therapy for patients with elevated
C-reactive protein levels after coronary stenting.4
Dr. Heider and colleagues have examined the levels of circu-
lating adhesion (E selectin, P selectin, soluble intercellular adhe-
sion molecule-1 (ICAM-1), and soluble vascular cell adhesion
molecule-1 (VCAM-1) and inflammatory monocyte chemoattrac-for claudication in 44 subjects. The study is limited in assessing
predictive values by a small patient cohort, particularly since only
32 of these patients received interventions, among which were a
mixture of angioplasty alone and stenting. Heterogeneity among
this small group in lesion anatomy, comorbid risk factors, and
medical therapies further limits the ability to discriminate associa-
tions with the biomarkers. However, the authors were able to
provide important new data on the nature and time course of the
inflammatory response to peripheral catheter-based procedures.
Their results suggest that angiography per se engenders an inflam-
matory response and offer the possibility that certain markers (E
selectin, P selectin, and VCAM-1) may be predictive of poor
outcome. Much larger (and likely multicenter) studies will need to
be conducted to accurately identify and validate biomarkers for
adverse outcomes after peripheral endovascular interventions.
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